Zobrazeno 1 - 10
of 33
pro vyhledávání: '"Jared C. Foster"'
Autor:
Alice P. Chen, James H. Doroshow, John J. Wright, Rene Costello, Donald Bottaro, Andrea Regier Voth, Naoko Takebe, Elad Sharon, Howard Streicher, Richard Piekarz, Robert Meehan, Lamin Juwara, Jared C. Foster, Lawrence Rubinstein, Ashley Bruns, Jennifer Zlott, Khanh T. Do, Warren A. Chow, Kristen Ganjoo, James Hu, Shivaani Kummar, Geraldine O'Sullivan Coyne
Supplementary Data from Clinical Activity of Single-Agent Cabozantinib (XL184), a Multi-receptor Tyrosine Kinase Inhibitor, in Patients with Refractory Soft-Tissue Sarcomas
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::18093bd7818563307195df58214a4506
https://doi.org/10.1158/1078-0432.22483926
https://doi.org/10.1158/1078-0432.22483926
Autor:
Alice P. Chen, James H. Doroshow, John J. Wright, Rene Costello, Donald Bottaro, Andrea Regier Voth, Naoko Takebe, Elad Sharon, Howard Streicher, Richard Piekarz, Robert Meehan, Lamin Juwara, Jared C. Foster, Lawrence Rubinstein, Ashley Bruns, Jennifer Zlott, Khanh T. Do, Warren A. Chow, Kristen Ganjoo, James Hu, Shivaani Kummar, Geraldine O'Sullivan Coyne
Purpose:Soft-tissue sarcomas (STS) are a rare, heterogeneous group of mesenchymal tumors. For decades the mainstay of treatment for advanced, unresectable STS has been palliative chemotherapy. High levels of activated MET receptor have been reported
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::acae07441313ff191c17c7376293dd3a
https://doi.org/10.1158/1078-0432.c.6531276.v1
https://doi.org/10.1158/1078-0432.c.6531276.v1
Autor:
Elad Sharon, Jared C Foster
Publikováno v:
JNCI: Journal of the National Cancer Institute.
We consider the design of phase II trials evaluating combinations of experimental therapies. In the modern era, many immunotherapy and targeted therapy regimens are being developed as combination regimens, including combinations consisting only of ex
Autor:
Robert S. Meehan, Ashley Bruns, Lamin Jawara, Geraldine O'Sullivan Coyne, James C. Hu, Naoko Takebe, Alice P. Chen, S. Kummar, Andrea Regier Voth, Jared C. Foster, Howard Streicher, Kristen N. Ganjoo, Khanh T. Do, Rene Costello, Elad Sharon, Jennifer Zlott, Larry Rubinstein, Donald P. Bottaro, Warren A. Chow, John Wright, Richard Piekarz, James H. Doroshow
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research, vol 28, iss 2
Clin Cancer Res
Clin Cancer Res
Purpose: Soft-tissue sarcomas (STS) are a rare, heterogeneous group of mesenchymal tumors. For decades the mainstay of treatment for advanced, unresectable STS has been palliative chemotherapy. High levels of activated MET receptor have been reported
Autor:
Jane Perlmutter, Victoria S. Blinder, Laleh Amiri-Kordestani, Jared C. Foster, Eileen Rakovitch, Eric P. Winer, Angelo DiLeo, Julia White, Anthony D. Elias, Ana F. Best, Lynn Pearson Butler, Sara M. Tolaney, Lawrence Baizer, Patricia A. Spears, Elena Schwartz, David Cameron, Elizabeth Garrett-Mayer, Neelima Denduluri, Elizabeth S. Frank, Larissa A. Korde, E. Shelley Hwang, Nadine Tung, Judith M Bliss
Publikováno v:
M Tolaney, S, Garrett-Mayer, E, White, J, S. Blinder, V, C. Foster, J, Amiri Kordestani, L, Hwang, S, M. Bliss, J, Rakovitch, E, Perlmutter, J, A. Spears, P, Frank, E, M. Tung, N, D. Elias, A, Cameron, D A, Denduluri, N, F. Best, A, Di Leo, A, Baizer, L, Pearson Butler, L, Schwartz, E, P Winer, E & A. Korde, L 2021, ' Updated standardized definitions for efficacy endpoints in adjuvant breast cancer clinical trials: STEEP Version 2.0 ', Journal of Clinical Oncology . https://doi.org/10.1200/JCO.20.03613
J Clin Oncol
J Clin Oncol
PURPOSEThe Standardized Definitions for Efficacy End Points (STEEP) criteria, established in 2007, provide standardized definitions of adjuvant breast cancer clinical trial end points. Given the evolution of breast cancer clinical trials and improvem
Publikováno v:
JNCI: Journal of the National Cancer Institute. 112:128-135
Designing and interpreting single-arm phase II trials of combinations of agents is challenging because it can be difficult, based on historical data, to identify levels of activity for which the combination would be worth pursuing. We identified Canc
Autor:
Mohamad Adham Salkeni, Anthony Paul Conley, James Lin Chen, Elizabeth J. Davis, Melissa Amber Burgess, Albiruni Ryan Abdul Razak, Nancy Moore, Katherine V. Ferry-Galow, Kristin K. Fino, King Leung Fung, Ralph E. Parchment, Jared C. Foster, Christina Rosenberger, Geraldine Helen O'Sullivan Coyne, Naoko Takebe, Elad Sharon, James H. Doroshow, Alice P. Chen
Publikováno v:
Journal of Clinical Oncology. 40:11528-11528
11528 Background: Chondrosarcoma is one of the most common bone malignancies in adults, and the third most common in pediatric patients (pts). The most prevalent subtype, conventional chondrosarcoma, is a slow growing tumor that is historically known
Autor:
Nancy Moore, James H. Doroshow, Saiama N. Waqar, Christina L. Rosenberger, Mel Simpson, Richard Piekarz, Alida Palmisano, Funda Meric-Bernstam, Stephen Leong, Yingdong Zhao, P. Mickey Williams, Kanwal Pratap Singh Raghav, Richard Simon, Biswajit Das, S. Kummar, Larry Rubinstein, Chris Karlovich, David J. Sims, Mariam M. Konaté, Ming Chung Li, Eric C. Polley, Jared C. Foster, Alice P. Chen, Geraldine O'Sullivan Coyne, Chih Jian Lih
Publikováno v:
JCO Precision Oncology
PURPOSEThis trial assessed the utility of applying tumor DNA sequencing to treatment selection for patients with advanced, refractory cancer and somatic mutations in one of four signaling pathways by comparing the efficacy of four study regimens that
Autor:
Kathryn Lurain, Richard F. Little, Howard Streicher, Ravie Kem, Jared C. Foster, Elad Sharon, Joshua E. Reuss, Diana Stern, Ramya Ramaswami, Helen X. Chen
Publikováno v:
JAMA Network Open
Key Points Question Has inclusion of people living with HIV in anti–programmed death 1 and anti–programmed death ligand 1 (anti–PD1/PDL1) immunotherapy trials changed during ongoing Cancer Therapy Evaluation Program advocacy efforts by the Nati
Autor:
Jared C. Foster, Geraldine O'Sullivan Coyne, Naoko Takebe, Kristin Fino, Elad Sharon, James H. Doroshow, Ralph E. Parchment, Laura K Fogli, Alice P. Chen, Katherine V. Ferry-Galow, Suzanne George, James S. Hu, Anthony P. Conley, Richard F. Riedel, Melissa Amber Burgess, Nancy Moore, John Glod, Abdul Rafeh Naqash, Brian A. Van Tine, William L. Read
Publikováno v:
Journal of Clinical Oncology. 39:11519-11519
11519 Background: ASPS constitutes < 1% of soft tissue sarcomas and frequently presents in adolescents and young adults. There are no approved therapies for ASPS. We are currently evaluating the clinical activity of atezolizumab (atezo), an anti-PD-L